ROSELAND, NJ, March 2, 2021 (GLOBE NEWSWIRE) – Milestone Scientific Inc. (NYSE American: MLSS), A leading developer of computerized drug delivery instruments that provide virtually painless and accurate injections, today announced that it has started selling CompuFlo® / CathCheck ™ disposables to Medical University of South Carolina (MUSC). The MUSC University Medical Center is a nationally recognized and leading university in health sciences, recently ranked as the number one hospital in South Carolina. MUSC Health owns and operates eight hospitals and provides patient care throughout the state of South Carolina. .
Arjan Haverhals, president of Milestone Scientific, further noted: “We appreciate the support of Dr. Hebbar, Director of Obstetric Anesthesia, and her team at MUSC. This latest commercial order follows extensive testing by the MUSC team. This decision by another major US medical center further illustrates the favorable response to CathCheck and CompuFlo as we pursue our goal of becoming the new standard of treatment for epidural procedures. “
The clinical and safety benefits of the CompuFlo Epidural / CathCheck System are supported by extensive published clinical data that demonstrate significant reductions in epidural punctures, as well as complication rates, and contribute to anesthesiologists’ time savings. In addition, the CompuFlo instrument has the potential to significantly reduce the costs associated with morbidity, providing a direct economic benefit for health institutions. Likewise, CathCheck technology has the potential to transform monitoring of catheter placement after an epidural procedure, confirming placement of a catheter in 2 minutes, versus 20-40 minutes using conventional methods.
About Medical University of South Carolina (MUSC)
Founded in 1824, Medical University of South Carolina (MUSC) continues the tradition of excellence in education, research and patient care. MUSC educates and trains more than 3,000 students and nearly 800 residents at six colleges and has more than 17,000 employees. As the state’s only integrated health science academic center and largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $ 3.2 billion, with an annual economic impact of nearly $ 4 billion and annual research funding of more than $ 284 million.
As a clinical health system at the Medical University of South Carolina, MUSC Health is dedicated to providing high quality patient care available, while training generations of competent and compassionate health professionals to serve the people of South Carolina. and beyond. Comprised of approximately 1,600 beds, over 100 extension locations, MUSC College of Medicine, the doctors’ practice plan and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals located in Charleston, Chester, Florence counties , Lancaster and Marion. In 2020, for the sixth consecutive year, the US News & World Report named MUSC Health as the No. 1 hospital in South Carolina.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections accurate, efficient and virtually painless. Milestone®’s proprietary DPS Dynamic Pressure Sensing technology is our technology platform that advances the development of state-of-the-art devices, regulating flow rate and monitoring needle tip pressure, through platform extensions for local anesthesia for administration subcutaneous drug therapy, with specific applications for cosmetic injections of botulinum toxin, identification of the epidural space in regional anesthesia procedures and intra-articular joint injections. For more information, visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements relating to the time and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions that involve judgments regarding future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict with precision and many which are beyond Milestone control. Some of the important factors that could cause actual results to differ materially from those indicated in the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent decisions, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards and risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including, without limitation, Milestone’s Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based on management’s reasonable belief as of the date hereof. Milestone assumes no obligation to publicly review or update any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020